

0300

0300

0400

Patent  
Attorney's Docket No. 033532-001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Maurice ISRAËL et al.

Application No.: 10/051,243

Filed: January 22, 2002

For: METHODS FOR THE PREVENTION  
AND/OR THE TREATMENT OF  
GLUTAMATE CYTOTOXICITY

Group Art Unit: Unassigned

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTERAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER &amp; MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620By: Susan M. DadioSusan M. Dadio  
Registration No. 40,373Date: February 20, 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                                 |   |                            |
|---------------------------------|---|----------------------------|
| In re Patent Application of     | ) |                            |
|                                 | ) |                            |
| Maurice ISRAËL et al.           | ) | Group Art Unit: Unassigned |
|                                 | ) |                            |
| Application No.: 10/051,243     | ) |                            |
|                                 | ) |                            |
| Filed: January 22, 2002         | ) | Examiner: Unassigned       |
|                                 | ) |                            |
| For: METHODS FOR THE PREVENTION | ) |                            |
| AND/OR THE TREATMENT OF         | ) |                            |
| GLUTAMATE CYTOTOXICITY          | ) |                            |
|                                 | ) |                            |



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited and the International Search Report is enclosed.

**U.S. PATENT DOCUMENTS**

1. CHAPDELAINE et al., U.S. Patent No. 5,254,683, issued October 19, 1993.

**FOREIGN PATENT DOCUMENTS**

1. MICHIELS, PCT Publication Number WO 98/51291, published November 19, 1998.
2. MIYAGAKI et al., European Patent Publication Number 0 146 338 A2, published June 26, 1985.

3. BLACHE et al., European Patent Publication Number 0 631 777 A1, published January 4, 1995.

**OTHER DOCUMENTS**

1. MATTEI et al., "Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes," *Neuroscience Letters*, 1999, pp. 183-86, vol. 271, Elsevier Science Ireland Ltd., Ireland.
2. AZZA et al., "Lipid Peroxidation and Lysosomal Integrity in Different Inflammatory Models in Rats: The Effects of Indomethacin and Naftazone," *Pharmacological Research*, 1995, pp. 279-85, The Italian Pharmacological Society, Italy.
3. ZICOT, "Etude multicentrique de l'efficacite et de la tolerance de la naftazone (Mediaven® 10 MG). Comparaison de deux schemas posologiques," *Revue Medicale De Liege*, April, 1993, pp. 224-28, France.
4. HERBER et al., "Reduction and Glucuronidation of Naftazone by Human and Rat Liver Microsomes," *Drug Metabolism and Disposition*, 1995, pp. 1305-14, Vol. 23, No. 12, The American Society for Pharmacology and Experimental Therapeutics, Bethesda, Maryland, USA.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).


This Information Disclosure Statement contains information which is not in the English language but was cited in an International Search Report in a counterpart foreign application. A copy of the International Search Report is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

  
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: February 20, 2002